This multicentre, double-blind, placebo-controlled, parallel-group study determined the efficacy and safety of GW660511 200 mg, a dual inhibitor of angiotensinconverting enzyme (ACE) and neutral endopeptidase (NEP), in mild-to-moderate hypertensive patients (diastolic blood pressure (DBP), X90 and p109 mm Hg; systolic blood pressure (SBP), X150 and p180 mm Hg). After a single-blind 2-to 4-week placebo run-in period, 123 patients (aged 18-65 years) were randomized to either placebo (n ¼ 62) or to active treatment (n ¼ 61) consisting of two consecutive 3-day dose titration periods of GW660511X 50 mg once daily and 100 mg once daily followed by GW660511X 200 mg once daily for 14 days. GW660511X 200 mg significantly lowered (baseline and placebo-corrected) both trough mean cuff SBP (À8.00 mm Hg, P ¼ 0.002) and DBP (À5.38 mm Hg, P ¼ 0.003). GW660511X 200 mg significantly reduced placebo-corrected mean 24-h and daytime but not night-time ambulatory SBP and DBP. Over the 0-24 h time period following GW660511X 200 mg, there were significant (Po0.001) reductions in serum ACE activity and significant (Po0.001) increases in plasma ANP concentration compared with placebo in terms of both peak and trough effects. In addition, treatment with GW660511X 200 mg significantly (P ¼ 0.003) increased (placebo-corrected, 1.52-fold) urinary excretion of cGMP over the 0-24 h interval. Treatment-related adverse events were experienced by 43% of the patients administered GW660511X 200 mg and 44% of those dosed with placebo with headache the most commonly reported. In conclusion, GW660511X 200 mg is an effective antihypertensive in mild-to-moderate hypertensive patients with potent effects on biological markers of ACE and NEP inhibition.
Introduction
Suppression of the renin-angiotensin system (RAS) with angiotensin-converting enzyme (ACE) inhibitors has been generally accepted as a valuable therapeutic approach in hypertension. In addition to reducing blood pressure (BP), suppression of the RAS with ACE inhibitors is able to protect against the target-organ damage that results from hypertension. 1 However, regardless of the type of medication used, only 40-50% of hypertensive patients achieve goal BP of o140/90 mm Hg with monotherapy. 2 Vasopeptidase inhibitors are single molecules that simultaneously inhibit the activity of ACE and neutral endopeptidase (NEP), an enzyme involved in the metabolism of several peptides. By inhibiting the RAS and potentiating the natriuretic peptide system at the same time, vasopeptidase inhibitors reduce vasoconstriction and enhance vasodilatation, thereby decreasing peripheral vascular resistance and BP. 3 Consequently, vasopeptidase inhibitors may offer advantages over currently available monotherapies in terms of greater BP reduction, improved endothelial function and reduced cardiovascular events. 4, 5 Several members of the vasopeptidase inhibitor class have entered clinical development: omapatrilat, sampatrilat, fasidotrilat, gemopatrilat, mixanpril, MDL100240 and GW660511X. 6 These compounds differ in their relative potency for inhibiting ACE versus NEP. 7, 8 Clinical evidence thus far has shown that omapatrilat, sampatrilat and fasidotril are effective in the management of hypertension in different patient populations. [9] [10] [11] [12] [13] [14] However, adverse events (AE) associated with omapatrilat, especially angioedema, raised a concern for the safety of vasopeptidase inhibitors. 15 GW660511X is a novel potent and selective dual inhibitor of ACE (IC 50 3.2 nM) and NEP (IC 50 1.8 nM) both in vitro and ex vivo. 16, 17 In a previous phase I study, a single oral dose (X200 mg) of GW660511X produced 480% inhibition of serum ACE activity at 2 h postdose and significant NEP inhibition based on an elevation of plasma ANP and cGMP concentrations. In addition, GW660511X pharmacokinetics revealed an elimination half-life of B12 h and was well tolerated at all doses, with the most frequently reported adverse event being headache. 17 The objective of this study was to evaluate the efficacy and safety of GW660511X 200 mg in a population with mild-to-moderate hypertension.
Patients and methods

Study population
Male or female patients, aged 18-65 years, with mild-to-moderate hypertension and with a body mass index in the range of 19-34 kg/m 2 were eligible for entry into the placebo run-in phase. Mildto-moderate hypertension was defined as a diastolic blood pressure (DBP) of X90 and p109 mm Hg and systolic blood pressure (SBP) of X150 and p180 mm Hg (mean of three readings). Patients were not included in the study if they had secondary hypertension, signs of orthostatic hypotension, diabetes mellitus, clinically significant hepatic or renal dysfunction, cardiac arrhythmias, myocardial infarction, a stroke or transient ischemic attack in the last 24 months, prior alcohol or drug abuse, intolerance to ACE or NEP or ACE/NEP inhibitors, or were currently taking any antihypertensive or other medication other than those specified in the study protocol.
Study design
This was a randomized, double-blind, placebocontrolled, parallel-group trial conducted at multiple centres in Germany and Australia in accordance with both Good Clinical Practice guidelines and the Declaration of Helsinki and its revisions. The protocol was approved by the relevant Ethics Committees for the participating centres and all patients gave written, informed consent before undergoing any examination or study procedure.
At the screening visit, each patient was examined and a medical history was obtained to determine whether the patient was suitable for inclusion in the study. Baseline and demographic characteristics were recorded. Patients on antihypertensive therapy had their medications tapered off and discontinued before entering a 2-to 4-week, single-blind, placeborun in period. Patients self-administered the placebo drug during the placebo run-in period and returned to the study unit weekly for BP monitoring. At the end of the placebo run-in period, patients were randomized to either GW665011X or placebo (1:1 ratio) treatment in a double-blind manner. Patients in the active treatment group received two consecutive 3-day dose titration periods of GW660511X 50 mg once daily (days 1-3) and then 100 mg once daily (days 4-6) followed by GW660511X 200 mg once daily for 14 days (days [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Patients in the placebo treatment group received the same dosing regimen with a matched placebo.
During the treatment period, all patients attended the study unit for the first 9 days, after which they were discharged home and self-administered study drug for the remaining 11 days except for days 7, 10, 13 and 14 of the post-titration dosing period, when they were dosed in the unit. Patients returned for follow-up assessment 7 and 14 days after the final dose of study medication.
End points and objectives
The primary efficacy end point was baseline and placebo-corrected decrease in trough (24-h) cuff SBP and trough cuff DBP following 14 days dosing with GW660511X 200 mg. Secondary efficacy end points included baseline and placebo-corrected treatment effect on 24-h weighted mean, daytime weighted mean and night-time weighted mean ABPM recordings of SBP and DBP. Additional objectives were to assess safety and tolerability and the effects of GW660511X 200 mg on various pharmacodynamic parameters.
Efficacy assessments
Blood pressure was measured using an automatic sphygmomanometer and appropriately sized cuff. Measurements were taken at pre-dose and 1, 2, 3, 4 and 12 h post-dose on day À1 (the day before dosing), days 2-9 and on day 19. On days 1 and 20, cuff BP was measured pre-dose and 1, 2, 3, 4, 6, 8, 12, 16 and 24 h post-dose. Each measurement was made in the same arm after the patient had been supine for at least 10 min. At the pre-dose and 24 h post-dose assessments, three measurements were recorded; the mean value was calculated and was rounded up or down to the nearest whole number.
At the end of the placebo run-in period (day À1) and on day 19, 24-h ambulatory BP was measured every 30 min during daytime hours (0600-2300) and every 60 min during night-time hours (2300-0600).
Safety assessments
Safety was assessed by means of clinical review, 12-lead electrocardiograms and clinical laboratory evaluations including clinical chemistry, haematology and urinalysis. All AE from screening to the end of the study were collected. The severity of an AE was defined based on a qualitative evaluation by the investigator.
Pharmacodynamic measurements
Serial blood samples for ACE activity determination were collected in vacutainers at the following time points: pre-dose, 0.5, 1, 2, 4, 8, 12 and 24 h post-dose on day 1; pre-dose, 0.5, 1, 2, 3, 4, 8, 12, 16, 24, 36 and 48 h post-dose on day 20. For atrial natriuretic peptide (ANP) concentration determination, blood samples were collected on days 1 and 20, at predose, 0.5, 1, 2, 4, 8, 12 and 24 h post-dose into chilled EDTA collection tubes containing a cocktail of protease inhibitors (aprotinin: 500 KIU/ml plasma, plus soybean trypsin inhibitor: 50 BAEE U/ml plasma). Blood samples for plasma angiotensin I and angiotensin II determination were collected on day 1, at pre-dose into chilled EDTA collection tubes containing a mixture of protease inhibitors (aprotinin: 500 KIU/ml plasma, plus soybean trypsin inhibitor: 50 BAEE U/ml plasma). Blood serum or plasma was separated by centrifugation (1500 g for 15 min at 41C) and then stored at À801C until analysis. Serum samples were analysed for ACE activity using a validated fluorescence assay using the specific ACE substrate hip-his-leu with a limit of quantification of 0 ACE U/l. Plasma ANP concentration was analysed using an immunoradiometric assay (Shionogi & Co, Ltd, Osaka, Japan) with a limit of quantification of 5 pg/ml. Plasma angiotensin I and II were analysed by ELISA (Peninsula Laboratories, Belmont, CA, USA) with limits of quantification of 5 and 1 pg/ml, respectively.
The 24-h urine samples were collected on days 1 and 20, pre-dose and after treatment to measure volume, urinary sodium and urinary excretion of cGMP. Urine sodium concentration was measured by autoanalyser using ion selective electrodes. For cGMP, urine was collected into chilled EDTA collection tubes and stored at À801C until analysis. Urine cGMP levels were determined by ELISA (R&D Systems) with a validated calibration range of 1.2-500 pmol/ml.
Sample size
Based on standard deviations of 12 mm Hg for SBP and 7.5 mm Hg for DBP, it was estimated that with 50 patients per treatment group, the study would have 90% power at the 5% significant level (two-tailed) to detect a baseline and placebo-corrected treatment decrease in trough cuff BP of 8 mm Hg for SBP and 5 mm Hg for DBP. We estimated that 12% of patients would either drop out or have missing data, and thus 114 patients were planned to be randomized.
Statistical methods
Data management and statistical analysis were performed using SAS software (version 8.1, SAS Institute Inc., Cary, NC, USA). The following treatment populations were analysed in this study: the 'safety' population was all patients who received at least one dose of randomized study medication; the 'efficacy' population was all patients who were randomized to and received study medication, and who were compliant with therapy; the 'Intensive Sampling' population was a subset of the efficacy population, who received at least one dose of study medication and who volunteered to provide blood samples for the analysis of the pharmacodynamic parameters.
For all efficacy end points, log-transformed data derived from the efficacy population were analysed by fitting a linear fixed-effect model with treatment group (GW660511X or placebo), baseline, centre and class of pre-study antihypertensive drug as fixed effects. Treatment group, centre and class of prestudy antihypertensive drug were fitted as categorical variables. Baseline was fitted as a continuous covariate. From this analysis, the difference (and 95% confidence interval (CI)) between the active treatment group and placebo was calculated.
No statistical analyses were performed on the safety data. All safety parameters were summarized and reported according to the actual treatment received.
For each patient in the intensive sampling population, pharmacodynamic peak effect and trough effect were calculated for serum ACE, ratio of plasma angiotensin I:angiotensin II (AI:AII ratio) and plasma ANP at day 20. For serum ACE, the peak effect was the minimum concentration over the 0-24 h time period. For plasma ANP and AI:AII ratio, the peak effect was the maximum value over the 0-24 h time period. The trough effect for all end points was the measurement at the 24 h time period. Urinary sodium and urinary excretion of cGMP over the 0-24 h time period were calculated for each patient in the efficacy population at day 20. Statistical analysis was performed on each of the above parameters after log transformation of the data. A linear fixed effect model was fitted with terms for treatment group (GW660511X or placebo), baseline and centre. Treatment group and centre were fitted as categorical factors. Baseline was fitted as a continuous covariate. From this analysis, the ratio (and 95% confidence interval) between the active treatment group and placebo was calculated.
The association between change in BP (SBP and DBP) and change in ACE and NEP activities was analysed by mixed-effects models. Using patients as random effects and hours as replicates, mixed models were performed at days 1 and 20. Withinday changes in SBP and DBP were modelled separately, with treatment, per cent change in ACE activity and per cent change in ANP concentration as predictors. From this analysis, P-values of mixed model analysis of variance predicting change in SBP and DBP at days 1 and 20 were calculated with values o0.05 considered statistically significant.
Analysis of covariance was used to compare the changes from baseline for all efficacy end points and pharmacodynamic parameters in the two treatment groups, with a value of P ¼ 0.05 as the minimum level of significance.
Results
Patient disposition and baseline characteristics
At the end of the placebo run-in period, 123 patients were randomized to double-blind treatment ( Figure 1 ) and comprised the safety population. Based on the assessment of diary cards, one subject in the GW660511X group was deemed non-compliant and therefore the efficacy population consisted of 122 subjects.
In total, eight patients withdrew from treatment during the double-blind phase, three in the placebo group and five in the GW660511X group. The reasons for discontinuation after randomization were withdrawal of consent (two patients), unsatisfactory therapeutic effect (one patient), AE (three patients), arrhythmia (one patient) and early followup (one patient).
The two treatment groups were comparable with respect to demographics and baseline characteristics (Table 1 ). Most patients (36 patients (58%) in the placebo group and 40 (66%) in the GW660511X group) had been diagnosed with hypertension at least 4 years before their entry into the study. In total, 58% of patients in the placebo group and 51% of patients in the GW660511X group had been receiving prior antihypertensive medication. The most frequently used concomitant medications during the study were miscellaneous analgesics by 13 (21%) patients in the placebo group and 12 (20%) patients in the GW660511X group.
Efficacy
The effects of GW660511X 200 mg on BP are summarized in Table 2 . The baseline and placebocorrected effects for GW660511X 200 mg on mean trough cuff SBP (À8.00 mm Hg) and cuff DBP (À5.38 mm Hg) were statistically significant (SBP, 95% CI: À12.65, À3.35; P ¼ 0.002; DBP, 95% CI: À8.28, À2.48; P ¼ 0.003).
GW660511X 200 mg (placebo-adjusted) significantly reduced 24-h ambulatory mean SBP (P ¼ 0.03) and DBP (P ¼ 0.04), daytime ambulatory mean SBP (P ¼ 0.03) and DBP (P ¼ 0.05) but not night-time ambulatory mean SBP or DBP (both, P ¼ 0.15).
Pharmacodynamic analysis
The effects of GW660511X 200 mg on various pharmacodynamic parameters are summarized in Table 3 . Serum ACE activity, plasma AI:AII ratio and plasma ANP concentration were analysed in the intensive sampling population comprising 46 patients ( Figure 1 ). GW660511X 200 mg, compared with placebo, significantly reduced (Po0.001) peak and trough serum ACE activity and significantly increased (Po0.001) peak and trough plasma ANP concentrations, but did not alter plasma AI:AII ratios at peak (ratio ¼ 0.90; 95% CI: 0.40, 2.02) or trough (ratio ¼ 0.95; 95% CI: 0.44, 2.06). GW660511X 200 mg (placebo-corrected) increased the urinary excretion of cGMP (ratio ¼ 1.52; 95% CI: 1.29, 1.79) but did not alter excreted urine sodium (ratio ¼ 0.87; 95% CI: 0.66, 1.15). The amounts of excreted 24-h urine in the placebo and GW660511X groups were as follows: day 1 (pre-dose), 154719 and 177725 g, respectively; day 20, 168724 and 157723 g, respectively. After adjustment for baseline, the amount of excreted urine over the 24-h period on day 20 did not differ significantly between the treatment and placebo groups (P ¼ 0.26). Also, there were no significant within-group changes in excreted 24-h urine amounts for GW660511X (P ¼ 0.31) or placebo (P ¼ 0.41) over the course of the study.
The relationships between changes in serum ACE activity and plasma ANP concentration following GW660511X 200 mg and changes in BP (SBP and DBP) are summarized in Table 4 . There was a significant association (Po0.001) between GW660511X 200 mg treatment and change in SBP and DBP at day 20. When considered together after adjusting for treatment effect, change in plasma ANP concentration was the more powerful predictor (compared to change in serum ACE activity) of change in SBP (P ¼ 0.02) and DBP (P ¼ 0.006).
Safety
During the double-blind treatment, 74 AEs experienced by 26 (43%) patients in the GW665011X group and 106 AEs experienced by 27 (44%) patients in the placebo group were judged by the investigators to be drug-related but were mainly mild to moderate in intensity. The most frequently reported drug-related AEs are summarized in Table 5 . Headache was the most common treatment-related AE experienced by 14 (23%) patients in the GW660511X group and 19 (31%) patients in the placebo group. Two patients in the placebo treatment group had drug-related severe AEs: one patient had saphenous vein thrombosis and one had skin rash leading to study discontinuation. In the GW660511X 200 mg treated group, two patients experienced AEs that led to study withdrawal: one patient experienced gout that was judged not related to study drug and one patient experienced an elevation in liver enzymes (45 Â the upper limit of the normal range) that was judged related to study drug. No deaths occurred during the trial.
No clinically significant changes in vital signs and ECG recordings from baseline to the end of study were observed in either of the two treatment groups.
Discussion
The results of the present study demonstrate clearly that once-daily oral treatment with GW660511X 200 mg lowers BP effectively in patients with mildto-moderate hypertension. Moreover, GW660511X 200 mg treatment showed safety and tolerability comparable to those taking placebo overall, with an incidence of AE and withdrawal rates comparable in both treatment arms over the short duration of this relatively small trial. However, the one episode of elevated liver enzymes ascribed to GW660511X 200 mg led to patient withdrawal and is a notable concern.
Treatment with GW660511X 200 mg for 14 days resulted in mean baseline and placebo-corrected decrease in trough cuff SBP and DBP of 8.00 and 5.38 mm Hg, respectively. The magnitude of BP decrease after GW660511X 200 mg was comparable to that observed with other vasopeptidase inhibitors. In a 6-week randomized, double-blind study evaluating the efficacy of fasidotril 100 mg twice daily (n ¼ 27) compared with placebo (n ¼ 23) in patients with mild-to-moderate essential hypertension (supine DBP 95-114 mm Hg), the placebo subtracted decrease for supine trough cuff SBP/DBP was À7.4/À5.4 mm Hg.
14 In a 10-day double-blind, randomized controlled study, evaluating the efficacy of samaptrilat 50, 100 and 200 mg/day compared with lisinopril 20 mg/day and placebo in 124 patients with mild-to-moderate hypertension (supine DBP 95-115 mm Hg), the placebo subtracted reductions in supine trough cuff SBP/DBP were À5/À5, À8/À7 and À7/À4 mm Hg for 50, 100 and 200 mg sampatrilat, respectively. 12 In a placebocontrolled, dose-escalating study evaluating the efficacy and safety of omaptrilat in 717 patients with mild-to-moderate hypertension (seated DBP 95-110 mm Hg), reductions in baseline and placebocorrected trough cuff SBP/DBP were À7.5/À4.5, À13.1/À6.4, À13.6/À8.0 and À15.3/À8.5 mm Hg for the 20, 40, 60 and 80 mg doses of omapatrilat, respectively. 18 This study showed circadian differences on ABPM recordings of SBP and DBP. There were significant reductions in daytime but not night-time ABPM recordings of SBP and DBP following GW660511X compared with placebo. The lack of treatment effect at night time may warrant consideration of a night-time dose and could reflect the B12 h half-life that is, the pharmacokinetics of the drug. Although all 24-h, daytime and night-time BP measurements are powerful determinants of target organ damage, 19 daytime BP is generally considered as the main criterion for the diagnosis of hypertension based on ABPM, 20 and a better predictor of mortality from cardiovascular disease. 21 Patients with diabetes, renal dysfunction and secondary hypertension are frequently non-dippers (i.e. do not demonstrate BP decreases overnight) and were excluded from this study. Consequently, it is not possible to speculate what effect GW660511X might have on night-time BP in these patient subgroups.
Analysis of various pharmacodynamic parameters revealed that GW660511X 200 mg is a potent inhibitor of both ACE and NEP activities. The significant increase in urine cGMP excretion rate GW660511X 200 mg effects on BP were accompanied by significant inhibition of both ACE and NEP activities. However, the mixed model analysis of variance predicted that change in plasma ANP concentration resulting from the inhibition of NEP was the more powerful predictor of change in SBP and DBP (compared to change in serum ACE activity) within the study population of mild-tomoderate hypertensive patients. Thus, NEP and not ACE inhibition may have been the predominant contributor to the antihypertensive efficacy of GW660511X 200 mg over 14 days of treatment. However, the lack of a correlation between changes in circulating ACE and changes in SBP or DBP over the course of GW660511X treatment may have been at least partly explained by a more modest effect on tissue ACE, which was not measured in this study.
Treatment-emergent angioedema has been proposed to be a class effect of the vasopeptidase inhibitors. 15, 24 In earlier studies, the occurrence of angioedema was reported to be three times as frequent with omapatrilat as with enalapril (2.17 versus 0.68%). 15 Although AEs related to angioedema were not observed in the present study, this study was small (n ¼ 123) and of short duration (20 days in total). Accumulation of bradykinin or one of its metabolites (BK1-8) is believed to be involved in the occurrence of angioedema, 25, 26 and omapatrilat protects bradykinin from degradation and increases the production of BK1-8 by two-to threefold over GW660511X. 27 Consequently, the risk of angioedema may be less for GW660511X than for omapatrilat. However, studies of longer duration, in larger populations and in different ethnic groups are needed to further clarify the safety of GW660511X.
In summary (Table 6 ), GW660511X, a potent and selective inhibitor of ACE and NEP, was demonstrated to be an effective antihypertensive in patients with mild-to-moderate hypertension. Adverse events were comparable between patients administered GW660511X and placebo although one episode of abnormal liver enzymes warrants further investigation. Finally, the data suggest that NEP inhibition contributes more to BP reduction than ACE inhibition in patients administered GW660511X. Vasopeptidase inhibitors are effective antihypertensives but adverse events associated with omaptrilat, especially angioedema, raised a concern for the safety of these compounds What this study adds: K GW660511X is an effective hypertensive in mild-to-moderate hypertensive patients and its efficacy is comparable to that of other vasopeptidase inhibitors K GW660511X is a potent inhibitor of both ACE and NEP activities and NEP inhibition contributed more to BP reduction than ACE inhibition in mild-to-moderate hypertensive patients K The safety and tolerability profile of GW669511X is comparable to that of placebo K Varying the degree of ACE and NEP inhibition in a single molecule may alter the efficacy and safety risk profile Abbreviations: ACE, angiotensin-converting enzyme; BP, blood pressure; NEP, neutral endopeptidase.
